FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All Resources4G Clinical webinar - Mitigating Clinical Supply Chain Risk as the Pandemic Continues
Topics: COVID-19, Project Management, Supply Chain
Webinar
Free
Video on ACE Requirements
Topics: Pharma Industry, Strategic Planning
Video
Members
The Exponential Growth of Decentralized Trials, Direct-to-Patient and the Future of the Clinical Trials Landscape in Europe
Topics: Conference, Regulatory
Executive Summary
Members
